KINDAI UNIVERSITY


※苗字と名前の間にスペースをあけ、入力してください

米阪 仁雄ヨネサカ キミオ

プロフィール

所属部署名堺病院
職名診療講師/科長
学位
専門
ジャンル
コメンテータガイド
ホームページURL
メールアドレス
Last Updated :2017/09/15

研究活動情報

研究分野

  • 腫瘍学, 腫瘍治療学

研究キーワード

論文

  • DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance., Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J, International journal of cancer, 141, 8, 1682, 1689,   2017年10月, 査読有り
  • T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer., Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K, Molecular cancer therapeutics,   2017年08月, 査読有り
  • Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)., Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,   2017年05月, 査読有り
  • Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer., Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K, Cancer chemotherapy and pharmacology, 79, 3, 489, 495,   2017年03月, 査読有り
  • Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer., Yonesaka K, Hirotani K, von Pawel J, Dediu M, Chen S, Copigneaux C, Nakagawa K, Lung cancer (Amsterdam, Netherlands), 105, 1, 6,   2017年03月, 査読有り
  • HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy., Takegawa N, Yonesaka K, Clinical colorectal cancer,   2017年03月, 査読有り
  • Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G., Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K, Cancer science, 107, 12, 1843, 1850,   2016年12月, 査読有り
  • Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1., Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J, Oncotarget, 7, 51, 84860, 84871,   2016年12月, 査読有り
  • Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer., Ota T, Suzumura T, Sugiura T, Hasegawa Y, Yonesaka K, Makihara M, Tsukuda H, Tada T, Fukuoka M, Clinical case reports, 4, 5, 481, 485,   2016年05月, 査読有り
  • Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial., Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I, Cancer, 122, 7, 1050, 1059,   2016年04月, 査読有り
  • HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer., Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K, Oncotarget, 7, 3, 3453, 3460,   2016年01月, 査読有り
  • HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy., Kawakami H, Yonesaka K, Recent patents on anti-cancer drug discovery, 11, 3, 267, 274,   2016年, 査読有り
  • The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer., Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, Nishio K, Nakagawa K, Oncotarget, 6, 32, 33602, 33611,   2015年10月, 査読有り
  • Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer., Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K, Anticancer research, 35, 3, 1683, 1689,   2015年03月, 査読有り
  • Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer., Yonesaka K, Takegawa N, Satoh T, Ueda H, Yoshida T, Takeda M, Shimizu T, Chiba Y, Okamoto I, Nishio K, Tamura T, Nakagawa K, PloS one, 10, 11, e0143132,   2015年, 査読有り
  • The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells., Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K, Nakagawa K, Oncotarget, 5, 23, 11847, 11856,   2014年12月, 査読有り
  • Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity., Yonesaka K, Suzumura T, Tsukuda H, Hasegawa Y, Ozaki T, Sugiura T, Fukuoka M, Anticancer research, 34, 9, 5211, 5215,   2014年09月, 査読有り
  • Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia., Suzumura T, Yonesaka K, Tsukuda H, Fukuoka M, BMJ case reports, 2014,   2014年03月, 査読有り
  • Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization., Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M, Cancer research, 73, 22, 6770, 6779,   2013年11月, 査読有り
  • A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer., Hasegawa Y, Okamoto I, Takezawa K, Miyazaki M, Tsurutani J, Yonesaka K, Morinaga R, Tsuya A, Terashima M, Kudoh T, Azuma K, Kurata T, Nishikawa T, Fukuoka M, Nishimura Y, Nakagawa K, Investigational new drugs, 31, 3, 599, 604,   2013年06月, 査読有り
  • Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab., Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA, Science translational medicine, 3, 99, 99ra86,   2011年09月, 査読有り
  • Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis., Kawakami H, Sugioka K, Yonesaka K, Satoh T, Shimomura Y, Nakagawa K, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29, 23, e678, 9,   2011年08月, 査読有り
  • High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin., Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K, International journal of clinical oncology, 16, 3, 244, 249,   2011年06月, 査読有り
  • Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer., Okamoto I, Takeda K, Daga H, Miyazaki M, Yonesaka K, Kiyota H, Tsurutani J, Ueda S, Ichikawa Y, Takeda M, Sekiguchi R, Tominaga K, Enatsu S, Nambu Y, Nakagawa K, Lung cancer (Amsterdam, Netherlands), 70, 2, 168, 173,   2010年11月, 査読有り
  • Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells., Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K, Cancer research, 69, 16, 6515, 6521,   2009年08月, 査読有り
  • Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers., Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA, Clinical cancer research : an official journal of the American Association for Cancer Research, 14, 21, 6963, 6973,   2008年11月, 査読有り
  • Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells., Ikeda M, Okamoto I, Tamura K, Satoh T, Yonesaka K, Fukuoka M, Nakagawa K, Cancer letters, 248, 2, 292, 298,   2007年04月, 査読有り
  • Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin., Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K, International journal of cancer, 118, 4, 812, 820,   2006年02月, 査読有り

受賞

  •   2012年, 米国癌学会, 2012 Clinical Scholar award, AACR annual meeting
  •   2008年, 米国癌学会, 2008 Clinical Scholar award, AACR annual meeting
  •   2007年, IASLC, 2007 Young investigator award, World Conference on Lung Cancer
  •   2004年, 米国癌学会, 2004 Scholar Training award, AACR annual meeting

競争的資金

  • 文部科学省, 基盤研究(C), 頭頸部癌におけるセツキシマブ治療の耐性機序の解明 , 米阪 仁雄
  • 文部科学省, 基盤研究(C), HER2陽性乳癌、胃癌におけるheregulinによる抗HER2薬の効果予測